Peak Financial Management Inc. Has $316,000 Stake in Boston Scientific Corporation $BSX

Peak Financial Management Inc. decreased its holdings in Boston Scientific Corporation (NYSE:BSX) by 14.6% during the second quarter, Holdings Channel.com reports. The firm owned 2,945 shares of the medical equipment provider’s stock after selling 505 shares during the period. Peak Financial Management Inc.’s holdings in Boston Scientific were worth $316,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Sound Income Strategies LLC grew its stake in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares in the last quarter. 1248 Management LLC bought a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $27,000. Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $37,000. Finally, Activest Wealth Management grew its stake in shares of Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 373 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Leerink Partners increased their price target on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Truist Financial increased their price target on Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Finally, BTIG Research increased their price target on Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $120.71.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 in the last ninety days. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Up 0.9%

Shares of Boston Scientific stock opened at $96.73 on Thursday. The company’s fifty day simple moving average is $102.34 and its 200-day simple moving average is $101.96. The company has a market cap of $143.33 billion, a price-to-earnings ratio of 57.58, a PEG ratio of 2.31 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific’s quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the company posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.